$RKTO News

Rocket One shares are trading higher after the company announced it added SpaceXAI API to its AI technology stack.

Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement

Rocket One Regains Nasdaq Compliance

Rocket One Launches Swarm Stage AI™ to Counter Autonomous Drone Swarms

Rocket One (RKTO) Stock Is Trending After Hours As Retired NASA Astronaut Joins Advisory Board: Here's What You Need To Know

Rocket One Announces Former NASA Astronaut and International Space Station Commander Shane Kimbrough to Join Rocket One Space Advisory Board

ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD

Rocket One Increases At The Market Equity Offering To Up To $6.83M In Additional Common Stock Sales Under Sales Agreement With H C Wainwright & Co

Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology

From biotech to orbit: Rocket One's AI and space rebrand sends shares flying

HOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh Deals

Hoth Therapeutics Announces That Previously Disclosed Name Change To Rocket One, Trading Under Symbol 'RKTO,' To Take Effect May 28

Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Hoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH)

AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

Hoth Therapeutics Q1 EPS $(0.17) Up From $(0.27) YoY

Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Hoth Therapeutics Secures Regulatory Authorization In Spain For Phase 2a CLEER Trial Of HT-001